Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

S100A12 and S100A8/9 proteins are biomarkers of articular disease activity in Blau syndrome.

Wang L, Rosé CD, Foley KP, Anton J, Bader-Meunier B, Brissaud P, Chédeville G, Cimaz R, Fernández-Martín J, Guly C, Hachulla E, Harjacek M, Mackensen F, Merino R, Modesto C, Naranjo Hernández A, Pajot C, Ramanan AV, Thatayatikom A, Thomée C, Vastert S, Votta BJ, Bertin J, Wouters CH.

Rheumatology (Oxford). 2018 Apr 7. doi: 10.1093/rheumatology/key090. [Epub ahead of print]

PMID:
29635517
2.

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.

Weisel K, Scott NE, Tompson DJ, Votta BJ, Madhavan S, Povey K, Wolstenholme A, Simeoni M, Rudo T, Richards-Peterson L, Sahota T, Wang JG, Lich J, Finger J, Verticelli A, Reilly M, Gough PJ, Harris PA, Bertin J, Wang ML.

Pharmacol Res Perspect. 2017 Dec;5(6). doi: 10.1002/prp2.365.

3.

Identification of an antibody-based immunoassay for measuring direct target binding of RIPK1 inhibitors in cells and tissues.

Finger JN, Brusq JM, Campobasso N, Cook MN, Deutsch J, Haag H, Harris PA, Jenkins EL, Joglekar D, Lich JD, Maguire S, Nagilla R, Rivera EJ, Sun H, Votta BJ, Bertin J, Gough PJ.

Pharmacol Res Perspect. 2017 Dec;5(6). doi: 10.1002/prp2.377.

4.

The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase.

Haile PA, Votta BJ, Marquis RW, Bury MJ, Mehlmann JF, Singhaus R Jr, Charnley AK, Lakdawala AS, Convery MA, Lipshutz DB, Desai BM, Swift B, Capriotti CA, Berger SB, Mahajan MK, Reilly MA, Rivera EJ, Sun HH, Nagilla R, Beal AM, Finger JN, Cook MN, King BW, Ouellette MT, Totoritis RD, Pierdomenico M, Negroni A, Stronati L, Cucchiara S, Ziółkowski B, Vossenkämper A, MacDonald TT, Gough PJ, Bertin J, Casillas LN.

J Med Chem. 2016 May 26;59(10):4867-80. doi: 10.1021/acs.jmedchem.6b00211. Epub 2016 May 4.

PMID:
27109867
5.

Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.

Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L.

Bioorg Med Chem. 2015 Nov 1;23(21):7000-6. doi: 10.1016/j.bmc.2015.09.038. Epub 2015 Sep 25.

PMID:
26455654
6.

Catalytic in vivo protein knockdown by small-molecule PROTACs.

Bondeson DP, Mares A, Smith IE, Ko E, Campos S, Miah AH, Mulholland KE, Routly N, Buckley DL, Gustafson JL, Zinn N, Grandi P, Shimamura S, Bergamini G, Faelth-Savitski M, Bantscheff M, Cox C, Gordon DA, Willard RR, Flanagan JJ, Casillas LN, Votta BJ, den Besten W, Famm K, Kruidenier L, Carter PS, Harling JD, Churcher I, Crews CM.

Nat Chem Biol. 2015 Aug;11(8):611-7. doi: 10.1038/nchembio.1858. Epub 2015 Jun 10.

7.

The immune receptor NOD1 and kinase RIP2 interact with bacterial peptidoglycan on early endosomes to promote autophagy and inflammatory signaling.

Irving AT, Mimuro H, Kufer TA, Lo C, Wheeler R, Turner LJ, Thomas BJ, Malosse C, Gantier MP, Casillas LN, Votta BJ, Bertin J, Boneca IG, Sasakawa C, Philpott DJ, Ferrero RL, Kaparakis-Liaskos M.

Cell Host Microbe. 2014 May 14;15(5):623-35. doi: 10.1016/j.chom.2014.04.001. Epub 2014 Apr 17.

8.

A key role for the endothelium in NOD1 mediated vascular inflammation: comparison to TLR4 responses.

Gatheral T, Reed DM, Moreno L, Gough PJ, Votta BJ, Sehon CA, Rickard DJ, Bertin J, Lim E, Nicholson AG, Mitchell JA.

PLoS One. 2012;7(8):e42386. doi: 10.1371/journal.pone.0042386. Epub 2012 Aug 1.

9.
10.

Voltage-gated K+ currents in mouse articular chondrocytes regulate membrane potential.

Clark RB, Hatano N, Kondo C, Belke DD, Brown BS, Kumar S, Votta BJ, Giles WR.

Channels (Austin). 2010 May-Jun;4(3):179-91.

PMID:
20372061
11.

Functional characterization of TRPV4 as an osmotically sensitive ion channel in porcine articular chondrocytes.

Phan MN, Leddy HA, Votta BJ, Kumar S, Levy DS, Lipshutz DB, Lee SH, Liedtke W, Guilak F.

Arthritis Rheum. 2009 Oct;60(10):3028-37. doi: 10.1002/art.24799.

12.

Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: Part 2.

Willette RN, Bao W, Nerurkar S, Yue TL, Doe CP, Stankus G, Turner GH, Ju H, Thomas H, Fishman CE, Sulpizio A, Behm DJ, Hoffman S, Lin Z, Lozinskaya I, Casillas LN, Lin M, Trout RE, Votta BJ, Thorneloe K, Lashinger ES, Figueroa DJ, Marquis R, Xu X.

J Pharmacol Exp Ther. 2008 Aug;326(2):443-52. doi: 10.1124/jpet.107.134551. Epub 2008 May 22. Erratum in: J Pharmacol Exp Ther. 2011 Jul;338(1):408-9.

13.

N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I.

Thorneloe KS, Sulpizio AC, Lin Z, Figueroa DJ, Clouse AK, McCafferty GP, Chendrimada TP, Lashinger ES, Gordon E, Evans L, Misajet BA, Demarini DJ, Nation JH, Casillas LN, Marquis RW, Votta BJ, Sheardown SA, Xu X, Brooks DP, Laping NJ, Westfall TD.

J Pharmacol Exp Ther. 2008 Aug;326(2):432-42. doi: 10.1124/jpet.108.139295. Epub 2008 May 22. Erratum in: J Pharmacol Exp Ther. 2011 Jul;338(1):410.

14.

Interleukin-1 inhibits osmotically induced calcium signaling and volume regulation in articular chondrocytes.

Pritchard S, Votta BJ, Kumar S, Guilak F.

Osteoarthritis Cartilage. 2008 Dec;16(12):1466-73. doi: 10.1016/j.joca.2008.04.003. Epub 2008 May 20.

15.

A new dimeric dihydrochalcone and a new prenylated flavone from the bud covers of Artocarpus altilis: potent inhibitors of cathepsin K.

Patil AD, Freyer AJ, Killmer L, Offen P, Taylor PB, Votta BJ, Johnson RK.

J Nat Prod. 2002 Apr;65(4):624-7.

PMID:
11975520
16.

IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase.

Kumar S, Votta BJ, Rieman DJ, Badger AM, Gowen M, Lee JC.

J Cell Physiol. 2001 Jun;187(3):294-303.

PMID:
11319753
17.

Inhibition of p38 MAP kinase as a therapeutic strategy.

Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL.

Immunopharmacology. 2000 May;47(2-3):185-201. Review.

PMID:
10878289
18.

Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats.

Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, Bhatnagar PK, Lago AM, Callahan JF, DelMar EG, Miller MA, Nemeth EF, Fox J.

J Clin Invest. 2000 Jun;105(11):1595-604.

19.

CKbeta-8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues.

Votta BJ, White JR, Dodds RA, James IE, Connor JR, Lee-Rykaczewski E, Eichman CF, Kumar S, Lark MW, Gowen M.

J Cell Physiol. 2000 May;183(2):196-207.

PMID:
10737895
20.

Identification and cloning of a connective tissue growth factor-like cDNA from human osteoblasts encoding a novel regulator of osteoblast functions.

Kumar S, Hand AT, Connor JR, Dodds RA, Ryan PJ, Trill JJ, Fisher SM, Nuttall ME, Lipshutz DB, Zou C, Hwang SM, Votta BJ, James IE, Rieman DJ, Gowen M, Lee JC.

J Biol Chem. 1999 Jun 11;274(24):17123-31.

21.

Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.

Votta BJ, Levy MA, Badger A, Bradbeer J, Dodds RA, James IE, Thompson S, Bossard MJ, Carr T, Connor JR, Tomaszek TA, Szewczuk L, Drake FH, Veber DF, Gowen M.

J Bone Miner Res. 1997 Sep;12(9):1396-406.

22.

Cytokine suppressive anti-inflammatory compounds inhibit bone resorption in vitro.

Votta BJ, Bertolini DR.

Bone. 1994 Sep-Oct;15(5):533-8.

PMID:
7980964
23.

Effect of auranofin treatment on aberrant splenic interleukin production in adjuvant arthritic rats.

Lee JC, Dimartino MJ, Votta BJ, Hanna N.

J Immunol. 1987 Nov 15;139(10):3268-74.

PMID:
3500212
24.

Macrophage activation in rat models of inflammation and arthritis. Systemic activation precedes arthritis induction and progression.

Johnson WJ, Muirhead KA, Meunier PC, Votta BJ, Schmitt TC, DiMartino MJ, Hanna N.

Arthritis Rheum. 1986 Sep;29(9):1122-30.

PMID:
3489469

Supplemental Content

Loading ...
Support Center